To the problem of optimal antihypertensive therapy for patients with arterial hypertension and type 2 diabetes (according to the 2023 European Society of Hypertension Recommendations)

Posted on by adminLeave a comment

Ph.D. D.K. Miloslavsky, prof. S.M. Koval

Government Institution «L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine», Kharkiv

The review of the problem of optimal antihypertensive therapy for patients with arterial hypertension (AH) with type 2 diabetes mellitus (T2DM) through the prism of the 2023 European Society of Hypertension Guidelines examines the issues of diagnosis, prevention and treatment of very high-risk patients. In the historical aspect, the evolution of knowledge regarding this problem is considered, data on the epidemiology of comorbid pathology are given, attention is focused on the target levels of blood pressure and approaches to its monitoring. The authors comment on important population studies with a high level of evidence in this regard, touch on the aspects of prescribing new classes of drugs, namely mineralocorticoid receptor agonists and sodium-dependent glucose cotransporter type 2 inhibitors for reducing blood pressure and glycemia, considering the classes
and levels of evidence. At the end, the issue of prevention and treatment of manifestations of cardiovascular pathology in patients with type 2 diabetes is highlighted.

Key words: arterial hypertension, type 2 diabetes, 2023 European Society of Hypertension Guidelines, diagnosis, prevention and treatment, cardiovascular pathology.

https://doi.org/10.15407/internalmed2024.01.120

Download.PDF

Сite:

Милославський, Д.К. До проблеми оптимальної антигіпертензивної терапії хворих на артеріальну гіпертензію з цукровим діабетом 2 типу (за даними Рекомендацій Європейського товариства з гіпертензії 2023 року) / Д.К. Милославський, С.М. Коваль // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2024. – № 1. – С. 120-127. http://doi.org/10.15407/internalmed2024.01.120

Miloslavsky DK, Koval SM. [To the problem of optimal antihypertensive therapy for patients with arterial hypertension and type 2 diabetes (according to the 2023 European Society of Hypertension Recommendations)]. Shidnoevr. z. vnutr. simejnoi med. 2024;1:120-127. Ukrainian. http://doi.org/10.15407/internalmed2024.01.120

References:

Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. PMID: 30165516. doi: 10.1093/eurheartj/ehy339.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269-1324. doi: 10.1161/HYP.0000000000000066.

Unger T, Borghi C, Charchar F, Khan NA, et al. 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens. 2020 Jun;38(6):982-1004. doi: 10.1097/HJH.0000000000002453.

Cosentino F, Grant PJ, Aboyans V, Bailey CJ. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255-323. doi: 10.1093/eurheartj/ehz486.

Lin X, Xu Y, Pan X, Xu J, Ding Y, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020 Sep 8;10(1):14790. doi: 10.1038/s41598-020-71908-9.

Marx N, Federici M, Schütt K, Müller-Wieland D, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192. PMID: 37622663.

Downie ML, Ulrich EH, Noone DG. An update on hypertension in children with type 1 diabetes. Can J Diabetes. 2018;42:199-204. https://doi.org/10.1016/j.jcjd.2018.02.008

Norgaard K, Feldt-Rasmussen B, Borch-Johnsen K, Saelan H, Deckert T. Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:407-410. https://doi.org/10.1007/BF00404089

Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA, Hafez H. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg. 2010;52:55-61.e2. https://doi.org/10.1016/j.jvs.2010.02.012

Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6-14. https://doi.org/10.1046/j.1365-2125.2003.02007.x

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957-980.

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, et al.; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3337. https://doi.org/10.1093/eurheartj/ehab484

 Collado-Mesa F, Colhoun HM, Stevens LK, Boavida J, et al. Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabet Med. 1999;16:41-48. https://doi.org/10.1046/j.1464-5491.1999.00007.x

 Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension. 2021;78:1197-1205. https://doi.org/10.1161/HYPERTENSIONAHA.121.17981

DeFronzo RA, Ferrannini E, Groop L, Henry RR, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019. https://doi.org/10.1038/nrdp.2015.19

Redon J, Mancia G, Sleight P, Schumacher H, et al.; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74-83. https://doi.org/10.1016/j.jacc.2011.09.040

Whalen KL, Stewart RD. Pharmacologic management of hypertension in patients with diabetes. Am Fam Physician. 2008;78:1277-1282.

Grassi G, Biffi A, Dell’Oro R, Quarti Trevano F, et al. Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis. J Hypertens. 2020;38:1436-1442. https://doi.org/10.1097/HJH.0000000000002431

Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018;178:28-36. https://doi.org/10.1001/jamainternmed.2017.6015

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials. J Hypertens. 2018;36:1622-1636. https://doi.org/10.1097/HJH.0000000000001787

Narkiewicz K, Kjeldsen SE, Egan BM, Kreutz R, Burnier M. Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure. Blood Press. 2022;31:207-209. https://doi.org/10.1080/08037051.2022.2107483

Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603-615. https://doi.org/10.1001/jama.2014.18574

 Mancia G, Grassi G. Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. Diabetologia. 2018;61:517-525. https://doi.org/10.1007/s00125-017-4537-3

Miloslavskyi DK, Koval SM, Lytvinova OM. Cardiometabolic disorders in arterial hypertension and type 2 diabetes in wartime (literature review). Arterial Hypertens. 2023;16(3-4):12-22. doi: 10.22141/2224-1485.16.3-4.2023.352. 

Mancia G, Magrini F, Morganti A, Stella A, et al. In Memoriam: Alberto Zanchetti (Parma July 27, 1926 – Milan March 24, 2018). J Clin Hypertens (Greenwich). 2018 May;20(5):826-828. doi: 10.1111/jch.13315. PMID: 29878579.

Whelton PK, Flack JM, Jennings G, Schutte A, Wang J, Touyz RM. Editors’ Commentary on the 2023 ESH Management of Arterial Hypertension Guidelines. Hypertension. 2023;80:1795-1799. doi: 10.1161/HYPERTENSIONAHA.123.21592.

Barbato E, Azizi M, Schmieder RE, Lauder L, et al. Renal denervation in the management of hypertension in adults: a clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023 Apr 17;44(15):1313-1330. doi: 10.1093/eurheartj/ehad054. PMID: 36790101.

Ettehad D, Emdin CA, Kiran A, Anderson SG, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967 https://doi.org/10.1016/S0140-6736(15)01225-8

Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018;178:28-36. https://doi.org/10.1001/jamainternmed.2017.6015

Beddhu S, Chertow GM, Greene T, Whelton PK, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT. J Am Heart Assoc. 2018;7 https://doi.org/10.1161/JAHA.118.009326

 Buckley LF, Dixon DL, Wohlford GF, Wijesinghe DS, Baker WL, Van Tassell BW. Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care. 2017;40:1733-1738. https://doi.org/10.2337/dc17-1366

 ONTARGET Investigators: Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. https://doi.org/10.1056/NEJMoa0801317

 Nazarzadeh M, Bidel Z, Canoy D, Copland E, et al., Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant level data meta-analysis. Lancet Diabetes Endocrinol. 2022;10:645-654. https://doi.org/10.1016/S2213-8587(22)00172-3

 Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799-2810. https://doi.org/10.1161/CIRCULATIONAHA.110.016337

 Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922-944. https://doi.org/10.1097/HJH.0000000000001276

 Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352 https://doi.org/10.1136/bmj.i717

 Mancia G, Kjeldsen SE, Zappe DH, Holzhauer B, Hua TA, Zanchetti A, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37:955-964. https://doi.org/10.1093/eurheartj/ehv633

 Ilkun OL, Greene T, Cheung AK, Whelton PK, et al. The influence of baseline diastolic blood pressure on the effects of intensive blood pressure lowering on cardiovascular outcomes and all-cause mortality in type 2 diabetes. Diabetes Care. 2020;43:1878-1884. https://doi.org/10.2337/dc19-2047

Mancia G, Schumacher H, Redon J, Verdecchia P, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727-1736. https://doi.org/10.1161/CIRCULATIONAHA.110.008870

 Olsen E, Holzhauer B, Julius S, Kjeldsen SE, Larstorp ACK, Mancia G, et al. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. Blood Press. 2021;30:82-89. https://doi.org/10.1080/08037051.2020.1855968

Joseph JJ, Deedwania P, Acharya T, Aguilar D, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145-e759. https://doi.org/10.1161/CIR.0000000000001040

Al Ghorani H, Götzinger F, Böhm M, Mahfoud F. Arterial hypertension – Clinical trials update 2021. Nutr Metab Cardiovasc Dis. 2022;32(1):21-31. https://doi.org/10.1016/j.numecd.2021.09.007

Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157-1172. https://doi.org/10.1161/CIRCULATIONAHA.120.050686

Shen J, Huang YM, Song XN, Hong XZ, et al. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease. J Renin Angiotensin Aldosterone Syst. 2016;17:1470320316656481. https://doi.org/10.1177/1470320316656481

Ling S, Zaccardi F, Vlacho B, Li P, et al. All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK. Diabetes Obes Metab. 2023;25(1):132-143. https://doi.org/10.1111/dom.14856

Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo controlled trials. Lancet. 2022;400:1788-1801.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, et al., CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657. https://doi.org/10.1056/NEJMoa1611925

Perkovic V, Jardine MJ, Neal B, Bompoint S, et al., CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-2306. https://doi.org/10.1056/NEJMoa1811744

Reifsnider OS, Kansal AR, Wanner C, Pfarr E, et al. Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME Trial. Am J Kidney Dis. 2022;79:796-806. https://doi.org/10.1053/j.ajkd.2021.09.014

Ruilope LM, Agarwal R, Anker SD, Filippatos G, et al., FIDELIO-DKD Investigators. Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension. 2022;79:2685-2695. https://doi.org/10.1161/HYPERTENSIONAHA.122.19744

 Giugliano D, Scappaticcio L, Longo M, Caruso P, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:189. https://doi.org/10.1186/s12933-021-01366-8

Caruso I, Cignarelli A, Sorice GP, Natalicchio A, et al. Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies. Metabolites. 2022;12:183. https://doi.org/10.3390/metabo12020183

Rowbottom C.E. ESC Congress 2023. Clin Med. 2023;63:102214. https://doi.org/10.1016/j.eclinm.2023.102214

Sorte AG, Turankar TB, Sawale S, Acharya S, Shukla S.J. Critical analysis of American Heart Association And European Society Of Cardiology Guidelines for hypertension. Family Med Prim Care. 2023;12(8):1505-1510. https://doi.org/10.4103/jfmpc.jfmpc_2125_22

Saely CH, Schernthaner GH, Brix J, Klauser-Braun R, et al. [Individualising antihypertensive therapy in patients with diabetes. A guideline by the Austrian Diabetes Association (update 2023)]. Wien Klin Wochenschr. 2023;135(Suppl 1):147-156. https://doi.org/10.1007/s00508-023-02189-1

Salem AM, Harris D, Bray JJH, Obaid DR, Stephens JW, Halcox J. Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: A real-world national cohort analysis. Int J Cardiol. 2023;377:104-111. https://doi.org/10.1016/j.ijcard.2023.02.004

Yang Q, Zheng R, Wang S, Zhu J, et al. Systolic Blood Pressure Control Targets to Prevent Major Cardiovascular Events and Death in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Hypertension. 2023;80(8):1640-1653. https://doi.org/10.1161/HYPERTENSIONAHA.123.20954

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, et al. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255-323. https://doi.org/10.1093/eurheartj/ehz486

Camafort M, Redón J, Pyun WB, Coca A. Intensive blood pressure lowering: a practical review. Clin Hypertens. 2020;26(1):21. https://doi.org/10.1186/s40885-020-00153-z

Manolis AJ, Kallistratos MS, Camafort M, Coca A. How low should blood pressure be in patients with chronic coronary and cerebrovascular diseases. Eur J Intern Med. 2023;109:22-29. https://doi.org/10.1016/j.ejim.2023.01.007